Movement Alert｜Tempus AI Intraday Rise 5.01%, FDA Clearance for AI-Powered ECG-MR Tool Spurs Rally

Market Focus

Oct 05

On October 5, Tempus AI rose 5.01% in regular trading to trade at $80.69 per share, with turnover of $163 million.

The rise follows the company's recently obtained FDA 510(k) clearance for its Tempus ECG-MR medical device. This AI-powered tool analyzes electrocardiograms to identify patients with moderate or severe mitral regurgitation, potentially enhancing diagnostic efficiency for heart valve disorders. It represents another regulatory milestone for Tempus in applying artificial intelligence to cardiac care.

Tempus AI operates as a healthcare technology company, offering next-generation sequencing diagnostics and a suite of analytical services and tools to healthcare providers, pharmaceutical companies, and researchers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1120445086"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120445086\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120445086?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-05 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120445086","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Intraday Rise 5.01%, FDA Clearance for AI-Powered ECG-MR Tool Spurs Rally","media":"Market Focus","content":"<p><p>On October 5, Tempus AI rose 5.01% in regular trading to trade at $80.69 per share, with turnover of $163 million.</p><p>The rise follows the company's recently obtained FDA 510(k) clearance for its Tempus ECG-MR medical device. This AI-powered tool analyzes electrocardiograms to identify patients with moderate or severe mitral regurgitation, potentially enhancing diagnostic efficiency for heart valve disorders. It represents another regulatory milestone for Tempus in applying artificial intelligence to cardiac care.</p><p>Tempus AI operates as a healthcare technology company, offering next-generation sequencing diagnostics and a suite of analytical services and tools to healthcare providers, pharmaceutical companies, and researchers.</p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Intraday Rise 5.01%, FDA Clearance for AI-Powered ECG-MR Tool Spurs Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Intraday Rise 5.01%, FDA Clearance for AI-Powered ECG-MR Tool Spurs Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-05 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 5, Tempus AI rose 5.01% in regular trading to trade at $80.69 per share, with turnover of $163 million.</p><p>The rise follows the company's recently obtained FDA 510(k) clearance for its Tempus ECG-MR medical device. This AI-powered tool analyzes electrocardiograms to identify patients with moderate or severe mitral regurgitation, potentially enhancing diagnostic efficiency for heart valve disorders. It represents another regulatory milestone for Tempus in applying artificial intelligence to cardiac care.</p><p>Tempus AI operates as a healthcare technology company, offering next-generation sequencing diagnostics and a suite of analytical services and tools to healthcare providers, pharmaceutical companies, and researchers.</p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1120445086","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120445086","pubTimestamp":1791212905,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 5, Tempus AI rose 5.01% in regular trading to trade at $80.69 per share, with turnover of $163 million.The rise follows the company's recently obtained FDA 510(k) clearance for its Tempus...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动向提醒|腾邦人工智能盘中上涨5.01%，FDA批准人工智能心电图磁共振工具刺激反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On October 5, Tempus AI rose 5.01% in regular trading to trade at $80.69 per share, with turnover of $163 million.The rise follows the company's recently obtained FDA 510(k) clearance for its Tempus ECG-MR medical device. This AI-powered tool analyzes electrocardiograms to identify patients with moderate or severe mitral regurgitation, potentially enhancing diagnostic efficiency for heart valve disorders. It represents another regulatory milestone for Tempus in applying artificial intelligence to cardiac care.Tempus AI operates as a healthcare technology company, offering next-generation sequencing diagnostics and a suite of analytical services and tools to healthcare providers, pharmaceutical companies, and researchers.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}